A study on the levels of calmodulin and DNA in human lung cancer cells

British Journal of Cancer

Volumn 73, Issue 7, 1996, Pages 899-901

  Liu, G X ^a   Sheng, H F ^a   Wu, S ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Antagonist; Calmodulin; DNA; Flow cyometry; Lung cancer; Phosphodiesterase assay

Indexed keywords

CALMODULIN; CALMODULIN INHIBITOR; CELL DNA; PHOSPHODIESTERASE;

ARTICLE; CANCER CELL; CANCER GRADING; CANCER STAGING; CLINICAL ARTICLE; DNA CONTENT; FLOW CYTOMETRY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG CANCER; PRIORITY JOURNAL;

EID: 0029996388     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.160     Document Type: Article

References (19)

1. BOYNTON AL, WHITFIELD JF AND MACMANUS JP. (1980). Calmodulin stimulates DNA synthesis by rat liver cells. Biochem. Biophys. Res. Commun., 95, 745-749.
2. CHAFOULEAS JG, BOLTON WE, HIDAKA H, BOYD AE AND MEANS AR. (1982). Calmodulin and cell cycle: involvement in regulation of cell-cycle progression. Cell, 28, 41-50.
3. CRISS WE AND KAKJUCHI S. (1982). Calcium, calmodulin and cancer. Fed. Proc., 41, 2289-2291.
4. HAIT WN AND LAZO JS. (1986). Calmodulin: a potential target for cancer chemotherapeutic agents. J. Clin. Oncol., 4, 994-1012.
5. 388 cell lines. Cancer Res., 50, 1165-1169.
6. HAIT WN, GRAIS L, BENZ C AND CADMAN EC. (1985). Inhibition of growth of leukaemic cells by inhibitors of calmodulin: Phenothiazines and melittin. Cancer Chemother. Pharmacol., 14, 202-205.
7. HICKIE RA, WEI JW, BLYTH LM AND WONG DYW. (1983). Cation and calmodulin in normal and neoplastical cell growth regulation. Can. J. Biochem. Cell Biol., 61, 934-941.
8. LAZO JS, HAIT WN, KENNEDY KA, BRAUN ID AND MEANDZIJA B. (1985). Enhanced bleomycin-induced DNA damage and cytotoxicity with calmodulin antagonists. Mol. Pharmacol., 27, 387-393.
9. JINGSHENG L, YE L AND YINCHANG C. (1985). Preparation and assay of calmodulin. Acta Academiae Medicinae Sinicae (China), 7, 453-458.
10. MEANS AS AND RASMUSSEN CD. (1988). Calcium, calmodulin and cell proliferation. Cell Calcium, 9, 313-319.
11. MILLER RL, BUKOWSKI RM, BUDD T, PURVIS J, WEICK JK AND SHEPARD K. (1988). Clinical modulation of doxorubicin resistance by the calmodulin-inhibitor, Trifluoperazine: a phase I/II trial. J. Clin. Oncol., 6, 880-888.
12. MOON TD, MORLEY JE, VESSELLA RL, LEVINE AS, PETERSON G AND LANGE PH. (1983). The role of calmodulin in human renal cell carcinoma. Biochem. Biophys. Res. Commun., 114, 843-849.
13. SASAKI Y AND HIDAKA H. (1982). Calmodulin and cell proliferation. Biochem. Biophys. Res. Commun., 104, 451-456.
14. SINGER AL, SHERWIN RP, DUNN AS AND APPLEMAN MM. (1976). Cycle nucleotide phosphodiesterase in neoplastic and nonneoplastic human mammary tissue. Cancer Res., 36, 60-66.
15. TAKEMOTO D AND JILKA C. (1983). Increased content of calmodulin in human leukaemia cells. Leuk. Res., 7, 97-100.
16. 388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors. Cancer Res., 42, 4730-4733.
17. 2+-dependent phosphodiesterase. In Methods in Enzymology, Sidey PC and Nathan OK (eds). pp. 39-47. Academic Press: London.
18. WEI JW AND HICKIE RA. (1981). Increased content of calmodulin in Morris Hepatoma 5123 t.c. (h). Biochem. Biophys. Res. Commun., 100, 1562-1568.
19. WEI JW, MORRIS HP AND HICKIE RA. (1982). Positive correlation between calmodulin content and hepatoma growth rates. Cancer Res., 42, 2571-2574.